Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
|
|
Nexvet Biopharma plc (NVET)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/13/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/10/2017 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 08/08/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/02/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/02/2017 |
4
| McCracken Joseph S (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 16,400 shares
@ $6.72, valued at
$110.2k
|
|
| 08/02/2017 |
4
| Lismore Damian T. (CFO) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 67,750 shares
@ $6.72, valued at
$455.3k
Disposed/sold 21,239 shares
@ $6.72, valued at
$142.7k
Disposed/sold 18,724 shares
@ $6.72, valued at
$125.8k
Disposed/sold 27,500 options to buy
@ $0.125, valued at
$3.4k
Disposed/sold 48,750 options to buy
@ $0.125, valued at
$6.1k
Disposed/sold 100,000 options to buy
@ $15, valued at
$1.5M
|
|
| 08/02/2017 |
4
| Kilty Cormac G (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 10,800 shares
@ $6.72, valued at
$72.6k
Disposed/sold 144,364 shares
@ $6.72, valued at
$970.1k
|
|
| 08/02/2017 |
4
| HORN JURGEN (Chief Product Development Ofcr) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 15,750 shares
@ $6.72, valued at
$105.8k
Disposed/sold 60,000 options to buy
@ $5.1, valued at
$306k
Disposed/sold 47,250 options to buy
@ $0.125, valued at
$5.9k
|
|
| 08/02/2017 |
4
| Heffernan Mark (CEO) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 109,810 shares
@ $6.72, valued at
$737.9k
Disposed/sold 243,587 shares
@ $6.72, valued at
$1.6M
Disposed/sold 50,000 options to buy
@ $0.125, valued at
$6.3k
Disposed/sold 106,929 options to buy
@ $0.125, valued at
$13.4k
Disposed/sold 4,833 options to buy
@ $0.125, valued at
$604.1
Disposed/sold 9,203 options to buy
@ $0.125, valued at
$1.2k
Disposed/sold 52,040 options to buy
@ $6.35, valued at
$330.5k
Disposed/sold 100,000 options to buy
@ $15, valued at
$1.5M
|
|
| 08/02/2017 |
4
| Hanna Ashraf (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 16,020 shares
@ $6.72, valued at
$107.7k
Disposed/sold 1,500 shares
@ $6.72, valued at
$10.1k
|
|
| 08/02/2017 |
4
| Gunn George W (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 42,600 shares
@ $6.72, valued at
$286.3k
Disposed/sold 1,500 options to buy
@ $0.125, valued at
$187.5 |
|
| 08/02/2017 |
4
| Farrell Geraldine T (VP Operations, General Counsel) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 18,980 shares
@ $6.72, valued at
$127.5k
Disposed/sold 33,180 shares
@ $6.72, valued at
$223k
Disposed/sold 30,000 options to buy
@ $0.125, valued at
$3.8k
Disposed/sold 4,678 options to buy
@ $0.125, valued at
$584.8
Disposed/sold 20,000 options to buy
@ $15, valued at
$300k
|
|
| 08/02/2017 |
4
| Brown Christopher Nigel (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 7,200 shares
@ $6.72, valued at
$48.4k
Disposed/sold 8,800 shares
@ $6.72, valued at
$59.1k
Disposed/sold 3,600 options to buy
@ $0.125, valued at
$450
Disposed/sold 7,080 options to buy
@ $0.125, valued at
$885 |
|
| 08/02/2017 |
4
| PATEL RAJIV A (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Disposed/sold 13,580 shares
@ $6.72, valued at
$91.3k
Disposed/sold 1,000 options to buy
@ $6.595, valued at
$6.6k
|
|
| 08/02/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/02/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/31/2017 |
RW
| Form RW - Registration Withdrawal Request: |
| 07/31/2017 |
8-K
| Quarterly results |
| 07/31/2017 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 07/10/2017 |
8-K
| Form 8-K - Current report: |
| 07/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/05/2017 |
4
| Kilty Cormac G (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 3,600 options to buy
@ $0.125, valued at
$450 |
|
| 07/05/2017 |
4
| HORN JURGEN (Chief Product Development Ofcr) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 15,750 options to buy
@ $0.125, valued at
$2k
|
|
| 07/05/2017 |
4
| Farrell Geraldine T (VP Operations, General Counsel) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 10,000 options to buy
@ $0.125, valued at
$1.3k
Exercised 2,340 options to buy
@ $0.125, valued at
$292.5
Exercised 2,866 options to buy
@ $0.125, valued at
$358.3
Exercised 6,194 options to buy
@ $0.125, valued at
$774.3 |
|
| 07/05/2017 |
4
| Brown Christopher Nigel (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 3,600 options to buy
@ $0.125, valued at
$450 |
|
| 07/05/2017 |
4
| McCracken Joseph S (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 500 options to buy
@ $0.125, valued at
$62.5
Exercised 3,600 options to buy
@ $0.125, valued at
$450 |
|
| 07/05/2017 |
4
| Hanna Ashraf (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 500 options to buy
@ $0.125, valued at
$62.5
Exercised 3,600 options to buy
@ $0.125, valued at
$450 |
|
| 07/05/2017 |
4
| Gunn George W (Director) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 500 options to buy
@ $0.125, valued at
$62.5
Exercised 3,600 restricted stock units
@ $0.125, valued at
$450 |
|
| 07/05/2017 |
4
| Lismore Damian T. (CFO) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 65,000 options to buy
@ $0.125, valued at
$8.1k
Exercised 16,250 options to buy
@ $0.125, valued at
$2k
Exercised 4,000 options to buy
@ $0.125, valued at
$500
Exercised 7,079 options to buy
@ $0.125, valued at
$884.9 |
|
| 07/05/2017 |
4
| Heffernan Mark (CEO) has filed a Form 4 on Nexvet Biopharma plc|
Txns:
| Exercised 25,000 options to buy
@ $0.125, valued at
$3.1k
Exercised 35,643 options to buy
@ $0.125, valued at
$4.5k
|
|
| 07/05/2017 |
8-K
| Form 8-K - Current report |
| 07/05/2017 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|